MX374472B - Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. - Google Patents

Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Info

Publication number
MX374472B
MX374472B MX2016012176A MX2016012176A MX374472B MX 374472 B MX374472 B MX 374472B MX 2016012176 A MX2016012176 A MX 2016012176A MX 2016012176 A MX2016012176 A MX 2016012176A MX 374472 B MX374472 B MX 374472B
Authority
MX
Mexico
Prior art keywords
tumor
cell therapy
adoptive cell
infiltrating lymphocytes
disclosed
Prior art date
Application number
MX2016012176A
Other languages
English (en)
Other versions
MX2016012176A (es
Inventor
Amod A Sarnaik
Hao Liu
Mark Mclaughlin
Shari Pilon-Thomas
Original Assignee
H Lee Moffitt Cancer Ct & Res
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res, Univ South Florida filed Critical H Lee Moffitt Cancer Ct & Res
Publication of MX2016012176A publication Critical patent/MX2016012176A/es
Publication of MX374472B publication Critical patent/MX374472B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para la expansión ex vivo de linfocitos infiltrantes de tumor para usar en la terapia celular adoptiva (ACT). También se describen composiciones y métodos para identificar un agente para la expansión ex vivo de linfocitos infiltrantes de tumor para usar en la ACT. También se describen métodos para el tratamiento del cáncer usando linfocitos infiltrantes de tumor expandidos mediante los métodos descritos.
MX2016012176A 2014-03-20 2015-03-20 Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. MX374472B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955970P 2014-03-20 2014-03-20
US201461973002P 2014-03-31 2014-03-31
PCT/US2015/021759 WO2015143328A1 (en) 2014-03-20 2015-03-20 Tumor-infiltrating lymphocytes for adoptive cell therapy

Publications (2)

Publication Number Publication Date
MX2016012176A MX2016012176A (es) 2017-04-13
MX374472B true MX374472B (es) 2025-03-06

Family

ID=54145388

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012176A MX374472B (es) 2014-03-20 2015-03-20 Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX2020005634A MX2020005634A (es) 2014-03-20 2016-09-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020005634A MX2020005634A (es) 2014-03-20 2016-09-20 Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.

Country Status (11)

Country Link
US (3) US20170081635A1 (es)
EP (2) EP3119477B1 (es)
JP (4) JP2017511375A (es)
KR (3) KR20230085225A (es)
CN (2) CN112080467A (es)
AU (3) AU2015231041B2 (es)
CA (1) CA2943389C (es)
EA (1) EA036386B1 (es)
ES (1) ES2776407T3 (es)
MX (2) MX374472B (es)
WO (1) WO2015143328A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036386B1 (ru) 2014-03-20 2020-11-03 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
EP3228701A1 (en) * 2016-04-05 2017-10-11 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
MA45595A (fr) 2016-07-07 2019-05-15 Iovance Biotherapeutics Inc Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
JP2019532652A (ja) 2016-10-26 2019-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド 凍結保存腫瘍浸潤リンパ球の再刺激
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018227810A1 (en) * 2017-03-01 2019-08-29 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
PE20251254A1 (es) 2017-05-24 2025-05-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
US11819517B2 (en) * 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN108486120B (zh) * 2018-04-28 2019-12-06 新乡医学院 一种新型CpG ODN序列及其在抗黑色素瘤上的应用
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
ES3036072T3 (en) 2018-11-05 2025-09-12 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
TW202206592A (zh) 2020-04-22 2022-02-16 美商艾歐凡斯生物治療公司 用於協調產製供病患特異性免疫治療之細胞的系統和方法
KR20230017786A (ko) 2020-04-28 2023-02-06 라이엘 이뮤노파마, 인크. 세포 배양 방법
CA3176654A1 (en) 2020-04-28 2021-11-04 Karl PEGGS T cell therapy
AU2021368569A1 (en) * 2020-10-27 2023-06-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus boosts t cell response for effective til therapy
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
US20240287456A1 (en) 2021-06-22 2024-08-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
US20230270784A1 (en) * 2021-12-07 2023-08-31 Memgen, Inc. Oncolytic virus boosts t cell response for effective til therapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
DK2332968T3 (en) 2003-11-05 2016-08-22 Dana Farber Cancer Inst Inc Alpha-helix peptides suitable for activating or inhibiting cell death
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
PT2327763T (pt) * 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Geração de células t específicas de antigénios
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2009062001A1 (en) 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
BR112012009962A2 (pt) * 2009-10-27 2015-09-15 Immunicum Ab método para a proliferação de células tantígeno específicas.
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
WO2013192628A1 (en) 2012-06-22 2013-12-27 University Of South Florida Peptoid-peptide hybrids and their use
CN103243072B (zh) * 2013-05-09 2016-03-02 杭州中赢生物医疗科技有限公司 CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法
CN103396992A (zh) * 2013-08-15 2013-11-20 中国人民解放军第二军医大学 寡克隆肝癌肿瘤浸润淋巴细胞的培养和应用
CN103520198B (zh) * 2013-09-24 2016-01-20 彭光勇 一种制备用于阻止肿瘤细胞诱导t细胞老化并逆转其免疫抑制能力的药物的方法及其在抗肿瘤免疫治疗中的用途
EA036386B1 (ru) * 2014-03-20 2020-11-03 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Проникающие в опухоль лимфоциты для адоптивной клеточной терапии

Also Published As

Publication number Publication date
CA2943389A1 (en) 2015-09-24
JP2020182477A (ja) 2020-11-12
CN106659913A (zh) 2017-05-10
AU2015231041A1 (en) 2016-11-03
US11518980B2 (en) 2022-12-06
CN112080467A (zh) 2020-12-15
CA2943389C (en) 2023-10-31
EP3119477A4 (en) 2018-03-07
MX2016012176A (es) 2017-04-13
JP2023123877A (ja) 2023-09-05
EP3119477B1 (en) 2020-01-01
US20170081635A1 (en) 2017-03-23
MX2020005634A (es) 2020-08-20
US20190177693A1 (en) 2019-06-13
ES2776407T3 (es) 2020-07-30
NZ762786A (en) 2024-05-31
JP2017511375A (ja) 2017-04-20
BR112016021370A2 (pt) 2017-08-15
AU2023200308A1 (en) 2023-03-02
AU2020256412A1 (en) 2020-11-26
EA036386B1 (ru) 2020-11-03
JP2025041755A (ja) 2025-03-26
KR20230085225A (ko) 2023-06-13
BR112016021370A8 (pt) 2021-07-20
AU2015231041B2 (en) 2020-07-16
KR20250004905A (ko) 2025-01-08
EP3698850A1 (en) 2020-08-26
US20220282215A1 (en) 2022-09-08
US12291724B2 (en) 2025-05-06
EP3119477A1 (en) 2017-01-25
WO2015143328A1 (en) 2015-09-24
EA201691866A1 (ru) 2017-01-30
KR20160146713A (ko) 2016-12-21

Similar Documents

Publication Publication Date Title
MX374472B (es) Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
GB2557123A (en) Modified cells and methods of therapy
SG10201902872YA (en) Ex vivo proliferation of epithelial cells
IL256160A (en) New peptides and their combination for use in immunotherapy and methods for creating scaffolds for use against pancreatic cancer and other types of cancer
TW201613648A (en) Compounds and compositions for immunotherapy
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
GB2570593A (en) Methods relating to intestinal organ-on-a-chip
PH12017500803A1 (en) Anti-pd-1 antibodies
GB201510771D0 (en) Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MX2015017103A (es) Celulas beta derivadas de células madre ( sc-beta ) y composiciones y métodos para generarlas.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
PH12017500787A1 (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2018002344A (es) Metodo para tratar el cancer.
MX383484B (es) Método para tratar el cáncer.
TW201612308A (en) Collector architecture layout design
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
PH12018502303A1 (en) Compositions and methods for bioengineered tissues
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
BR112019007365A2 (pt) métodos e composições para imunoterapia com tusc2
NZ744131A (en) Tumor-infiltrating lymphocytes for adoptive cell therapy

Legal Events

Date Code Title Description
FG Grant or registration